3 research outputs found
The rapid spread of SARS-COV-2 Omicron variant in Italy reflected early through wastewater surveillance
The SARS-CoV-2 Omicron variant emerged in South Africa in November 2021, and has later been identified worldwide,
raising serious concerns.
A real-time RT-PCR assay was designed for the rapid screening of the Omicron variant, targeting characteristic mutations
of the spike gene. The assay was used to test 737 sewage samples collected throughout Italy (19/21 Regions) between
11 November and 25 December 2021, with the aim of assessing the spread of the Omicron variant in the
country. Positive samples were also tested with a real-time RT-PCR developed by the European Commission, Joint
Research Centre (JRC), and through nested RT-PCR followed by Sanger sequencing.
Overall, 115 samples tested positive for Omicron SARS-CoV-2 variant. The first occurrence was detected on 7
December, in Veneto, North Italy. Later on, the variant spread extremely fast in three weeks, with prevalence of positive
wastewater samples rising from 1.0% (1/104 samples) in the week 5–11 December, to 17.5% (25/143 samples)
in the week 12–18, to 65.9% (89/135 samples) in the week 19–25, in line with the increase in cases of infection with
the Omicron variant observed during December in Italy. Similarly, the number of Regions/Autonomous Provinces in
which the variant was detected increased fromone in the first week, to 11 in the second, and to 17 in the last one. The
presence of the Omicron variant was confirmed by the JRC real-time RT-PCR in 79.1% (91/115) of the positive samples,
and by Sanger sequencing in 66% (64/97) of PCR amplicons
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males
The polymorphism L412F in TLR3 has been associated with several infectious diseases. However, the mechanism underlying this association is still unexplored. Here, we show that the L412F polymorphism in TLR3 is a marker of severity in COVID-19. This association increases in the sub-cohort of males. Impaired macroautophagy/autophagy and reduced TNF/TNFα production was demonstrated in HEK293 cells transfected with TLR3L412F-encoding plasmid and stimulated with specific agonist poly(I:C). A statistically significant reduced survival at 28 days was shown in L412F COVID-19 patients treated with the autophagy-inhibitor hydroxychloroquine (p = 0.038). An increased frequency of autoimmune disorders such as co-morbidity was found in L412F COVID-19 males with specific class II HLA haplotypes prone to autoantigen presentation. Our analyses indicate that L412F polymorphism makes males at risk of severe COVID-19 and provides a rationale for reinterpreting clinical trials considering autophagy pathways. Abbreviations: AP: autophagosome; AUC: area under the curve; BafA1: bafilomycin A1; COVID-19: coronavirus disease-2019; HCQ: hydroxychloroquine; RAP: rapamycin; ROC: receiver operating characteristic; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; TLR: toll like receptor; TNF/TNF-α: tumor necrosis factor